Background: Tigecycline, a novel glycylcycline class agent (first in class), has been utilized for serious multidrug-resistant (MDR) pathogen infections in several global locations for 1-3 years. This prospective in vitro multicenter trial evaluates nearly 4,000 pathogens from Japan (2006)(2007).
Conclusions:
Tigecycline was observed to be active against nearly all tested species from Japanese medical centers for year [2003] [2004] strains, and in this prospective sample report remains similarly active (2006-2007 isolates) . Resistant subsets (MRSA, ESBL enteric bacilli, MDR Acinetobacter spp.) were generally inhibited at USA-FDAsusceptible breakpoints for tigecycline. Possible use of tigecycline for some serious MDR infections in Japan should be considered.
InTroDUCTIon
Tigecycline, introduced in 2005, is the first glycylcycline to be used in human clinical practice worldwide. This semisynthetic agent was a derivative of minocycline that has a unique, bacteriostatic effect by binding to bacterial ribosomes in a manner preventing the two principal determinants of tetracycline resistance (efflux, ribosomal protection). Cross-or co-resistance of tigecycline with other drug classes among Gram-positive cocci, Enterobacteriaceae and Acinetobacter spp. is rare; therefore, potential applications in multidrug-resistant (MDR) species in Japan may facilitate improved clinical outcomes.
To evaluate a large collection of contemporary (2007) Gram-positive and -negative isolates, 19 medical centers in Japan were recruited to supplement an earlier (2003) (2004) sample. The selection of the organisms was to focus on those species of greatest concern regarding emerging antimicrobial resistance patterns detected in Japan and worldwide (Infectious Disease Society of America). A central laboratory design (JMI Laboratories, North Liberty, IA, USA) was employed to assure data accuracy via use of rigid quality control (QC), concurrent reviews by experienced directors and follow-up molecular methods (epidemiology, mechanisms of resistance, etc.). Testing of newer agents and novel classes (tigecycline) was emphasized by applications of reference susceptibility testing methods of the Clinical and Laboratory Standards Institute (CLSI).
MATErIALS AnD METhoDS
Bacterial isolates. A total of 3,902 bacterial isolates collected during 2007 in 19 medical centers located in Japan were evaluated as part of the SENTRY Antimicrobial Surveillance Program. The isolates were consecutively collected from bloodstream infections, skin and soft tissue infections, urinary tract infections and pneumonia in hospitalized patients according to a common protocol. Only isolates from documented infections were included in the study. Species identification was confirmed by the central monitor using standard biochemical tests and the Vitek System (bioMerieux, Hazelwood, MO), when necessary.
Antimicrobial susceptibility testing. All isolates were susceptibility tested using the broth microdilution method as described by the CLSI (formerly NCCLS). Fresh cation-adjusted Mueller-Hinton broth was used in validated panels manufactured by TREK Diagnostics (Cleveland, OH). Categorical interpretations for comparator antimicrobials were those found in M100-S18; breakpoints for tigecycline were those of the United States (US) Food and Drug Administration (FDA) or by Jones et al. (2007) . QC was performed using Escherichia coli ATCC 25922, S. aureus ATCC 29213 and Pseudomonas aeruginosa ATCC 27853; all QC results were within specified ranges as published in M100-S18. Enterobacteriaceae with elevated MIC values (≥2 mg/L) for ceftazidime and/or ceftriaxone and/or aztreonam were considered as extended-spectrum ß-lactamase (ESBL)-producing phenotypes. Acinetobacter spp., with imipenem or meropenem MICs ≥8 mg/L, and Enterobacteriaceae with imipenem or meropenem MICs at ≥2 mg/L, were screened for metallo-ß-lactamase (MBL) enzymes and OXA-23, -24, and -58 enzymes by PCR. Enterobacteriaceae with an ertapenem MIC at >1 mg/L were screened for KPC-type serine carbapenemases. Organisms exhibiting unusual resistant antibiograms were also subjected to molecular analyses.
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rESULTS
• Nineteen medical centers in Japan participated in the Prospective Phase of this tigecycline study (2007 (Tables 2 and 3) .
-E. cloacae (3 isolates) with elevated carbapenem MIC results having IMP-1 (2) or IMP-21 (1) metallo-ß-lactamases. -P. mirabilis isolates producing CTX-M-2 from nine hospitals and showing clonal spread.
-S. agalactiae (13 hospitals) with fluoroquinolone resistance; QRDR mutations (two per isolate) were noted ( Table 2 ). -S. pneumoniae with MDR patterns, some showing greater resistance to extended spectrum cephalosporins compared to penicillin G. -Acinetobacter spp. were usually susceptible to most agents but two strains produced one or more carbapenemases (OXA-58 + IMP-1, A. lwoffii; OXA-23).
• P. aeruginosa continues to harbor metallo-ß-lactamases (IMP-1, IMP-7, VIM-2) with evidence of intra-and intercenter spread (Table 3) .
ConCLUSIonS
• Tigecycline exhibited excellent activity against contemporary (2007) Japanese isolates (except P. aeruginosa) 
